These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 18833044)

  • 1. Safe use of efalizumab in a psoriasis patient with chronic heart failure due to hypertrophic cardiomyopathy.
    Cassano N; Miracapillo A; Buquicchio R; Mastrandrea V; Vena GA
    G Ital Dermatol Venereol; 2008 Apr; 143(2):167. PubMed ID: 18833044
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term treatment of plaque psoriasis with efalizumab: an Italian experience.
    Costanzo A; Peris K; Talamonti M; Di Cesare A; Fargnoli MC; Botti E; Chimenti S
    Br J Dermatol; 2007 Apr; 156 Suppl 2():17-23. PubMed ID: 17371319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical management with efalizumab of a patient with psoriasis and comorbid vitiligo.
    Fernandez-Obregon AC
    J Drugs Dermatol; 2008 Jul; 7(7):679-81. PubMed ID: 18664161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of familial benign chronic pemphigus in a patient undergoing treatment with efalizumab for psoriasis.
    Santos-Juanes J; Coto-Segura P; Saavedra J; Laviano S; Galache C
    J Eur Acad Dermatol Venereol; 2009 May; 23(5):605-6. PubMed ID: 18759787
    [No Abstract]   [Full Text] [Related]  

  • 5. Multiple side effects of Efalizumab in a Saudi female with chronic persistent psoriasis followed by severe rebound after Efalizumab discontinuation.
    Bukhari IA
    Saudi Med J; 2007 Nov; 28(11):1745-7. PubMed ID: 17965804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of efalizumab and acitretin in chronic plaque psoriasis.
    Gisondi P; Girolomoni G
    J Eur Acad Dermatol Venereol; 2008 Feb; 22(2):247-8. PubMed ID: 18211428
    [No Abstract]   [Full Text] [Related]  

  • 7. Repigmentation of vitiligo during efalizumab.
    Wakkee M; Assen YJ; Thio HB; Neumann HA
    J Am Acad Dermatol; 2008 Aug; 59(2 Suppl 1):S57-8. PubMed ID: 18625392
    [No Abstract]   [Full Text] [Related]  

  • 8. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
    Papp KA; Miller B; Gordon KB; Caro I; Kwon P; Compton PG; Leonardi CL;
    J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S164-70. PubMed ID: 16488338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab rescue of efalizumab withdrawal flare and psoriasis-precipitated depression.
    Yip L; Harrison S; Foley P
    Australas J Dermatol; 2008 Nov; 49(4):250-1. PubMed ID: 18855796
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Heart failure in hypertrophic cardiomyopathy].
    Arq Bras Cardiol; 1992 Aug; 59(2):135-9. PubMed ID: 1341159
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of nail psoriasis with efalizumab: a preliminary study.
    Lamerson C; Stevens G; Sax K
    Cutis; 2008 Sep; 82(3):217-20. PubMed ID: 18856162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Novacor installation in a case of severe heart failure at the terminal stage caused by dilated hypertrophic cardiomyopathy].
    Nushimura M
    Kyobu Geka; 2012 Sep; 65(10):880. PubMed ID: 23189761
    [No Abstract]   [Full Text] [Related]  

  • 14. Congestive heart failure in dialysis patients.
    Parfrey PS; Harnett JD; Griffiths SM; Gault MH; Barré PE
    Arch Intern Med; 1988 Jul; 148(7):1519-25. PubMed ID: 3382298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of death from congestive heart failure in hypertrophic cardiomyopathy.
    Ikeda H; Maki S; Yoshida N; Murohara T; Adachi H; Koga Y; Imaizumi T
    Am J Cardiol; 1999 Apr; 83(8):1280-3, A9. PubMed ID: 10215301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
    J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis.
    Papp KA; Ho V; Langley R; Lynde C; Poulin Y; Shear N; Toole J; Zip C
    J Cutan Med Surg; 2006; 9 Suppl 1():26-32. PubMed ID: 16633859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comment on "Development of monoclonal gammopathy in 12 patients receiving efalizumab treatment for chronic plaque psoriasis".
    Ginarte M
    J Am Acad Dermatol; 2011 Jun; 64(6):1184; author reply 1184-5. PubMed ID: 21571182
    [No Abstract]   [Full Text] [Related]  

  • 19. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
    Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
    JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Apical hypertrophic cardiomyopathy as a cause of cardiac insufficiency in an 84-year-old woman--a case report].
    Grabysa R
    Kardiol Pol; 2008 Feb; 66(2):179-82. PubMed ID: 18344156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.